Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment

Neurobiology of Aging

Volumn 31, Issue 11, 2010, Pages 1877-1884

  Buchhave, Peder ^a,b   Zetterberg, Henrik ^c   Blennow, Kaj ^c   Minthon, Lennart ^a,b   Janciauskiene, Sabina ^b   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Beta Amyloid; Mild cognitive impairment; TNF; Tumor necrosis factor; Tumor necrosis factor receptor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; TAU PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; COGNITION DISORDERS; DEMENTIA, VASCULAR; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REFERENCE VALUES; SOLUBILITY; STATISTICS, NONPARAMETRIC;

EID: 77956933314     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.10.012     Document Type: Article

References (51)

1. Aderka D., Engelmann H., Shemer-Avni Y., Hornik V., Galil A., Sarov B., Wallach D. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res. 1992, 11:157-159.
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
3. Alvarez A., Cacabelos R., Sanpedro C., Garcia-Fantini M., Aleixandre M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol. Aging 2007, 28:533-536.
4. Association A.P. Diagnostic and Statistical Manual of Mental Disorders (DSM-III) 1987, American Psychiatric Association, Washington, DC.
5. Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol. 2005, 110:345-359.
6. Beutler B.A., Milsark I.W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J. Immunol. 1985, 135:3972-3977.
7. Blasko I., Lederer W., Oberbauer H., Walch T., Kemmler G., Hinterhuber H., Marksteiner J., Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 2006, 21:9-15.
8. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
9. Botchkina G.I., Meistrell M.E., Botchkina I.L., Tracey K.J. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol. Med. 1997, 3:765-781.
10. Davies L., Wolska B., Hilbich C., Multhaup G., Martins R., Simms G., Beyreuther K., Masters C.L. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988, 38:1688-1693.
11. Diez-Ruiz A., Tilz G.P., Zangerle R., Baier-Bitterlich G., Wachter H., Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol. 1995, 54:1-8.
12. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest. 2005, 115:1121-1129.
13. Garlind A., Brauner A., Hojeberg B., Basun H., Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res. 1999, 826:112-116.
14. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos L., Younkin L.H., Suzuki N., Younkin S.G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 1995, 270:7013-7016.
15. Hallenbeck J.M. The many faces of tumor necrosis factor in stroke. Nat. Med. 2002, 8:1363-1368.
16. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2007, 23:316-320.
17. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5:228-234.
18. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging 2008, 10.1016/j.neurobiolaging.2008.03.027.
19. Hasegawa Y., Sawada M., Ozaki N., Inagaki T., Suzumura A. Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. Gerontology 2000, 46:185-188.
20. He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., Staufenbiel M., Li R., Shen Y. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J. Cell Biol. 2007, 178:829-841.
21. Jia J.P., Meng R., Sun Y.X., Sun W.J., Ji X.M., Jia L.F. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci. Lett. 2005, 383:12-16.
22. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
23. Kreuzer K.A., Rockstroh J.K., Sauerbruch T., Spengler U. A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-alpha. J. Immunol. Methods 1996, 195:49-54.
24. Laird F.M., Cai H., Savonenko A.V., Farah M.H., He K., Melnikova T., Wen H., Chiang H.C., Xu G., Koliatsos V.E., Borchelt D.R., Price D.L., Lee H.K., Wong P.C. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005, 25:11693-11709.
25. Lantz M., Malik S., Slevin M.L., Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990, 2:402-406.
26. Li R., Yang L., Lindholm K., Konishi Y., Yue X., Hampel H., Zhang D., Shen Y. Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J. Neurosci. 2004, 24:1760-1771.
27. Liao Y.F., Wang B.J., Cheng H.T., Kuo L.H., Wolfe M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 2004, 279:49523-49532.
28. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
29. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
30. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
31. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., Dafre A.L., Di Giunta G., Figueiredo C.P., Takahashi R.N., Campos M.M., Calixto J.B. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci. 2007, 27:5394-5404.
32. Paganelli R., Di Iorio A., Patricelli L., Ripani F., Sparvieri E., Faricelli R., Iarlori C., Porreca E., Di Gioacchino M., Abate G. Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp. Gerontol. 2002, 37:257-263.
33. Patel N.S., Paris D., Mathura V., Quadros A.N., Crawford F.C., Mullan M.J. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J. Neuroinflamm. 2005, 2:9.
34. Perry R.T., Collins J.S., Wiener H., Acton R., Go R.C. The role of TNF and its receptors in Alzheimer's disease. Neurobiol. Aging 2001, 22:873-883.
35. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256:183-194.
36. Richartz E., Stransky E., Batra A., Simon P., Lewczuk P., Buchkremer G., Bartels M., Schott K. Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease?. J. Psychiatr. Res. 2005, 39:535-543.
37. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., Moody D.M., O'Brien M.D., Yamaguchi T., Grafman J., Drayer B.P., Bennett D.A., Fisher M., Ogata J., Kokmen E., Bermejo F., Wolf P.A., Gorelick P.B., Bick K.L., Pajeau A.K., BeU M.A., DeCarli C., Culebras A., Korczyn A.D., Bogousslavsky J., Hartmann A., Scheinberg P. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
38. Sambamurti K., Kinsey R., Maloney B., Ge Y.W., Lahiri D.K. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J. 2004, 18:1034-1036.
39. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
40. Tarkowski E., Blennow K., Wallin A., Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 1999, 19:223-230.
41. Tarkowski E., Liljeroth A.M., Nilsson A., Ricksten A., Davidsson P., Minthon L., Blennow K. TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD. Neurology 2000, 54:2077-2081.
42. Tobinick E.L., Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J. Neuroinflamm. 2008, 5:2.
43. Wakita H., Tomimoto H., Akiguchi I., Lin J.X., Ihara M., Ohtani R., Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res. 2003, 992:53-59.
44. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006, 5:655-660.
45. Wang Q., Wu J., Rowan M.J., Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur. J. Neurosci. 2005, 22:2827-2832.
46. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
47. Yamamoto M., Kiyota T., Horiba M., Buescher J.L., Walsh S.M., Gendelman H.E., Ikezu T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol. 2007, 170:680-692.
48. Yasutake C., Kuroda K., Yanagawa T., Okamura T., Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:402-406.
49. Zetterberg H., Andreasson U., Hansson O., Wu G., Andersson M.E., Buchhave P., Londos E., Umek R.M., Minthon L., Simon A.J., Blennow K. Cerebrospinal fluid BACE1 activity in Alzheimer's disease-relation to amyloid and axonal damage markers. Arch. Neurol. 2008, 65:1102-1107.
50. Zhao M., Cribbs D.H., Anderson A.J., Cummings B.J., Su J.H., Wasserman A.J., Cotman C.W. The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain. Neurochem. Res. 2003, 28:307-318.
51. Zuliani G., Ranzini M., Guerra G., Rossi L., Munari M.R., Zurlo A., Volpato S., Atti A.R., Ble A., Fellin R. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J. Psychiatr. Res. 2007, 41:686-693.